Clinical Trial Update: Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intratumoral delivery of saRNA particles expressing IL-12 for head and neck cancers is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Oral Cavity Cancer

Drugs mentioned

• IL-12 expressing saRNA intratumoral therapy (VLP platform)

Snippet

Sponsor: VLP Therapeutics | Conditions: Head and Neck Cancers- Squamous Cell, Head and Neck Cancer | Phase 1 | Status: RECRUITING